Clinical outcome of high-dose-rate interstitial brachytherapy in patients with oral cavity cancer

Purpose To evaluate the clinical outcome of high-dose-rate (HDR) interstitial brachytherapy (IBT) in patients with oral cavity cancer. Materials and Methods Sixteen patients with oral cavity cancer treated with HDR remote-control afterloading brachytherapy using 192Ir between 2001 and 2013 were analyzed retrospectively. Brachytherapy was administered in 11 patients as the primary treatment and in five patients as salvage treatment for recurrence after the initial surgery. In 12 patients, external beam radiotherapy (50-55 Gy/25 fractions) was combined with IBT of 21 Gy/7 fractions. In addition, IBT was administered as the sole treatment in three patients with a total dose of 50 Gy/10 fractions and as postoperative adjuvant treatment in one patient with a total of 35 Gy/7 fractions. Results The 5-year overall survival of the entire group was 70%. The actuarial local control rate after 3 years was 84%. All five recurrent cases after initial surgery were successfully salvaged using IBT ± external beam radiotherapy. Two patients developed local recurrence at 3 and 5 months, respectively, after IBT. The acute complications were acceptable (≤grade 2). Three patients developed major late complications, such as radio-osteonecrosis, in which one patient was treated by conservative therapy and two required surgical intervention. Conclusion HDR IBT for oral cavity cancer was effective and acceptable in diverse clinical settings, such as in the cases of primary or salvage treatment.

[1]  R. Tishler,et al.  Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. , 2011, International journal of radiation oncology, biology, physics.

[2]  M. Kaplan,et al.  Intensity-modulated radiotherapy for oral cavity squamous cell carcinoma: patterns of failure and predictors of local control. , 2011, International journal of radiation oncology, biology, physics.

[3]  I. Hsu,et al.  American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy. , 2011, International journal of radiation oncology, biology, physics.

[4]  Emma Hall,et al.  Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial , 2011, The Lancet. Oncology.

[5]  K. Muralidhar,et al.  Acquisition of equal or better planning results with interstitial brachytherapy when compared with intensity-modulated radiotherapy in tongue cancers. , 2010, Brachytherapy.

[6]  Vratislav Strnad,et al.  GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  P. Levendag,et al.  Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences. , 2007, International journal of radiation oncology, biology, physics.

[8]  C. Fournier,et al.  Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[9]  P. Frankel,et al.  Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck cancer. , 2005, International journal of radiation oncology, biology, physics.

[10]  N. Tomita,et al.  Treatment results of stage I oral tongue cancer with definitive radiotherapy. , 2005, Oral oncology.

[11]  N. Kakimoto,et al.  Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  Y. Yamazaki,et al.  Management of mandibular osteoradionecrosis corresponding to the severity of osteoradionecrosis and the method of radiotherapy , 2003, Head & neck.

[13]  S. Tung,et al.  High dose rate brachytherapy for early stage oral tongue cancer , 2002, Head & neck.

[14]  Lawrence E. Reinstein,et al.  A system for comprehensive 3D validation of localization, planning and treatment delivery for IMRT , 2001 .

[15]  T. Komori,et al.  High-dose rate interstitial brachytherapy for stage I-II tongue cancer. , 2000, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[16]  P. Wludyka,et al.  High‐Dose‐Rate Brachytherapy for Primary Carcinomas of the Oral Cavity and Oropharynx , 1999, The Laryngoscope.

[17]  M Fujita,et al.  Interstitial brachytherapy for stage I and II squamous cell carcinoma of the oral tongue: factors influencing local control and soft tissue complications. , 1999, International journal of radiation oncology, biology, physics.

[18]  M. Fujita,et al.  Treatment results of stage I and II oral tongue cancer with interstitial brachytherapy: maximum tumor thickness is prognostic of nodal metastasis. , 1998, International journal of radiation oncology, biology, physics.

[19]  É. Luporsi,et al.  Role of Interstitial Brachytherapy in Oral and Oropharyngeal Carcinoma: Reflection of a Series of 1344 Patients Treated at the Time of Initial Presentation , 1996, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[20]  W. Threlfall,et al.  Seven fractions of twice daily high dose-rate brachytherapy for node-negative carcinoma of the mobile tongue results in loss of therapeutic ratio. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  H. Shibuya,et al.  Brachytherapy for stage I & II oral tongue cancer: an analysis of past cases focusing on control and complications. , 1993, International journal of radiation oncology, biology, physics.

[22]  C. Paine,et al.  Interstitial brachytherapy: past-present-future. , 1991, International journal of radiation oncology, biology, physics.

[23]  L. Delclos,et al.  Primary radiotherapy in the treatment of stage I and II oral tongue cancers: importance of the proportion of therapy delivered with interstitial therapy. , 1990, International journal of radiation oncology, biology, physics.

[24]  W. Mendenhall,et al.  Analysis of time-dose factors in squamous cell carcinoma of the oral tongue and floor of mouth treated with radiation therapy alone. , 1981, International journal of radiation oncology, biology, physics.

[25]  Y. Yoshioka,et al.  Phase III trial of high- vs. low-dose-rate interstitial radiotherapy for early mobile tongue cancer. , 2001, International journal of radiation oncology, biology, physics.